Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme.
Temozolomide (TMZ) is an oral alkylating agent used during concurrent and adjuvant chemotherapy for newly diagnosed glioblastoma multiforme. Temozolomide is generally well tolerated and improves survival; however, severe adverse events have occasionally been reported. Here, we report the case of a patient who developed aplastic anemia with related complications in the setting of concurrent TMZ treatment with radiotherapy. This case illustrates that aplastic anemia is a rare side effect of TMZ that can occur relatively early in the course of concurrent chemotherapy, and underscores the importance of clinician awareness of this potentially devastating side effect.
Oh
J
J
Division of Neurology, Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON. jiwon.oh@utoronto.ca
Kutas
G J
GJ
Davey
P
P
Morrison
M
M
Perry
J R
JR